Trial · NCT04813653
Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells
NCT04813653, Phase 1, Completed, Tel-Aviv Sourasky Medical Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells. Trials, record NCT04813653. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04813653
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells
- NCT number
- NCT04813653
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 3 participants, actual
- Lead sponsor
- Tel-Aviv Sourasky Medical Center
- Conditions
- Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
- Interventions
- cyclosporine in combination with carfilzomib and dexamethasone
- First posted
- 2021-03-24
- Last updated
- 2025-07-24
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment parameters. | follow-up 2 years post study | Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment parameters. |
| Secondary | Overall response rate ORR | follow-up 2 years post study | Proportion of patients who achieve a best overall response of stringent complete response , complete response, very good partial response, or partial response as defined using the IMWG criteria |
| Secondary | Progression free survival PFS | follow-up 2 years post study | The time from first dose to the date of the first documented tumor progression or death due to any cause. PFS will be determined by an investigator, based upon laboratory data, as defined by the IMWG criteria |
| Secondary | Duration of Response DOR | follow-up 2 years post study | The time between the date of first response to the date of the first objectively documented tumor progression as assessed by study steering committee according to modified IMWG criteria or death due to any cause prior to subsequent anti-cancer therapy. |
| Secondary | Time to Response TTR | follow-up 2 years post study | The time from the first dose to the date of the first sCR, CR, VGPR, or PR. |
| Secondary | Depth of Best Response (DpR) | follow-up 2 years post study | According to IMWG criteria. |
| Secondary | Time to progression (TTP) | follow-up 2 years post study | Time from initiation of treatment to documented PD |
| Secondary | Overall Survival (OS) | follow-up 2 years post study | Time between the date of first dose and the date of death due to any cause |
| Secondary | Extramedullary progression | follow-up 2 years post study | Kaplan Meyer test will be applied to test for differences between the groups in Progression Free Survival |
| Secondary | Extramedullary progression | follow-up 2 years post study | Kaplan Meyer test will be applied to test for differences between the groups in Overall Survival |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04813653
GET https://conductscience.org/api/trials/v1/NCT04813653/registered